J
Janet F. Eary
Researcher at National Institutes of Health
Publications - 201
Citations - 12244
Janet F. Eary is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Radioimmunotherapy & Positron emission tomography. The author has an hindex of 61, co-authored 200 publications receiving 11718 citations. Previous affiliations of Janet F. Eary include University of Washington & University of Alabama.
Papers
More filters
Journal ArticleDOI
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
Oliver W. Press,Janet F. Eary,Frederick R. Appelbaum,Paul J. Martin,Christopher C. Badger,Wil B. Nelp,Stephan D. Glenn,Greg Butchko,Darrell R. Fisher,Bruce A. Porter,Dana C. Matthews,LD Fisher,Irwin D. Bernstein +12 more
TL;DR: High-dose radioimmunotherapy with 131I-labeled antibodies is associated with a high response rate in patients with B-cell lymphoma in whom antibody biodistribution is favorable.
Journal ArticleDOI
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
Oliver W. Press,Oliver W. Press,F R Appelbaum,F R Appelbaum,Paul J. Martin,Paul J. Martin,Dana C. Matthews,Dana C. Matthews,Irwin D. Bernstein,Irwin D. Bernstein,Janet F. Eary,Wil B. Nelp,Ted Gooley,Stephan D. Glenn,Bruce A. Porter,D.R Fisher +15 more
TL;DR: 131I-anti-CD20 (B1) antibody therapy produces complete responses of long duration in most patients with relapsed B-cell lymphomas when given at maximally tolerated doses with autologous stem cell rescue.
Journal ArticleDOI
Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
Brian P. Rubin,Scott M. Schuetze,Janet F. Eary,Thomas H. Norwood,Sohail K. Mirza,Ernest U. Conrad,James D. Bruckner +6 more
TL;DR: The dramatic response seen in this patient demonstrates that inhibition of PDGFB receptor tyrosine kinase activity can significantly impact viability of at least one type of solid tumor.
Journal ArticleDOI
Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
Oliver W. Press,Janet F. Eary,Christopher C. Badger,Paul J. Martin,F R Appelbaum,Ronald Levy,Robert C. Miller,Sherri L. Brown,Wil B. Nelp,Kenneth A. Krohn +9 more
TL;DR: The tolerable toxicity and encouraging efficacy warrant further dose escalation in this phase I trial of anti-CD37 monoclonal antibody MB-1, and all five patients showed preferential localization and retention of MoAb at tumor sites.
Journal ArticleDOI
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.
Oliver W. Press,Janet F. Eary,Ted Gooley,Ajay K. Gopal,Stephen Liu,Joseph G. Rajendran,David G. Maloney,Stephen H. Petersdorf,Sharon A. Bush,Lawrence D. Durack,Paul J. Martin,Darrell R. Fisher,Brent L. Wood,James W. Borrow,Bruce A. Porter,Justin P. Smith,Dana C. Matthews,Frederick R. Appelbaum,Irwin D. Bernstein +18 more
TL;DR: The findings compare favorably with those in a nonrandomized control group of patients who underwent transplantation, external-beam total-body irradiation, and etoposide and cyclophosphamide therapy during the same period, even after adjustment for confounding variables in a multivariable analysis.